| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1052 | 2018 |
| The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ... Cancer discovery 9 (7), 910-925, 2019 | 256 | 2019 |
| Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies JJ Shatzel, SR Olson, DL Tao, OJT McCarty, AV Danilov, TG DeLoughery Journal of thrombosis and haemostasis 15 (5), 835-847, 2017 | 254 | 2017 |
| Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data D Sun, X Guan, AE Moran, LY Wu, DZ Qian, P Schedin, MS Dai, ... Nature biotechnology 40 (4), 527-538, 2022 | 148 | 2022 |
| The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells JC Godbersen, LA Humphries, OV Danilova, PE Kebbekus, JR Brown, ... Clinical cancer research 20 (6), 1576-1589, 2014 | 122 | 2014 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer cell 40 (8), 850-864. e9, 2022 | 103 | 2022 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma SK Agarwal, AH Salem, AV Danilov, B Hu, S Puvvada, M Gutierrez, ... British journal of clinical pharmacology 83 (4), 846-854, 2017 | 87 | 2017 |
| DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance AV Danilov, D Neupane, AS Nagaraja, EV Feofanova, LA Humphries, ... PloS one 6 (10), e26815, 2011 | 85 | 2011 |
| Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib MJ Gordon, M Churnetski, H Alqahtani, X Rivera, A Kittai, SM Amrock, ... Cancer 124 (15), 3192-3200, 2018 | 79 | 2018 |
| Cardiac non‐Hodgkin's lymphoma: clinical characteristics and trends in survival MJ Gordon, O Danilova, S Spurgeon, AV Danilov European journal of haematology 97 (5), 445-452, 2016 | 73 | 2016 |
| Targeted therapy in chronic lymphocytic leukemia: past, present, and future AV Danilov Clinical therapeutics 35 (9), 1258-1270, 2013 | 66 | 2013 |
| Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+ Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic … JG Gribben, W Jurczak, RW Jacobs, S Grosicki, K Giannopoulos, ... Blood 136, 37-39, 2020 | 63 | 2020 |
| Molecular pathogenesis of chronic lymphocytic leukemia AV Danilov, OV Danilova, AK Klein, BT Huber Current molecular medicine 6 (6), 665-675, 2006 | 62 | 2006 |
| Burkitt lymphoma international prognostic index AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ... Journal of clinical oncology 39 (10), 1129-1138, 2021 | 59 | 2021 |
| Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule, EA Kio, L Karlin, ... Clinical Cancer Research 26 (12), 2810-2818, 2020 | 59 | 2020 |
| Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs MJ Matasar, S Luminari, PM Barr, SK Barta, AV Danilov, BT Hill, ... The oncologist 24 (11), e1236-e1250, 2019 | 55 | 2019 |
| Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents C Paiva, JC Godbersen, A Berger, JR Brown, AV Danilov Cell death & disease 6 (7), e1807-e1807, 2015 | 55 | 2015 |
| Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia BM Holderness, S Malhotra, NB Levy, AV Danilov Journal of Clinical Oncology 31 (12), e197-e199, 2013 | 54 | 2013 |
| Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy IB Greenwell, AD Staton, MJ Lee, JM Switchenko, DF Saxe, JJ Maly, ... Cancer 124 (11), 2306-2315, 2018 | 51 | 2018 |
Tingting LiuUniversity of California, DavisVerifierad e-postadress på ucdavis.edu
